The study evaluates the use of a microfluidic device (FertileChip®, now ZyMot® ICSI) to reduce double-strand sperm DNA fragmentation, a factor associated with recurrent miscarriages and low implantation rates. In a pilot study with nine patients, the device reduced fragmentation by 46% compared to the conventional «swim-up» method. Subsequently, in 163 ICSI cycles, fertilization rates of 75.4% and ongoing pregnancy rates of 34% were achieved. The results suggest that this technology improves sperm selection and clinical outcomes in patients with high sperm DNA fragmentation.
